in the pathogenesis of IRDs (RetNet). Recently, NMNAT1, a gene involved in nicotinamide adenine dinucleotide (NAD) synthesis, was found to be responsible for a subset of LCA cases, mainly with macular lesions [6] [7] [8] [9] .
Earlier studies described three nicotinamide mononucleotide adenylyltransferases catalyzing the reaction of nicotinamide mononucleotide with ATP to form NAD + [10] , a crucial agent in many redox reactions especially important in the central nervous system. Whereas NMNAT2 and NMNAT3 localize to the Golgi apparatus and mitochondria, respectively, NMNAT1 is a nuclear isoform that was previously studied in the Wallerian degeneration, slow (Wlds) mouse model. In these mice, a fusion protein (Wlds) was identified, consisting of Ube4b and the complete coding sequence of Nmnat1. Subsequently, this fusion protein was found to have a protective effect on axonal degeneration after neuronal injury [11, 12] , and Nmnat1 activity was found to be required for this phenomenon [13] [14] [15] . Homozygous null mutations in this gene in Drosophila melanogaster and murine models result in early lethality. Heterozygous knockout mice displayed normal development [16] , and a retinal knockout in the fruit fly resulted in progressive retinal degeneration [17] . NAD + levels rapidly decreased in axons before their degeneration. However, retinal degeneration cannot probably be attributed to enzymatic activity of NMNAT1. An inactive Nmnat1 in Drosophila prevented photoreceptor degeneration [17] . Therefore, Perrault et al. hypothesized that this protein may have an additional chaperone function [9] .
The NMNAT1 mutations reported thus far were found throughout the entire coding sequence. Most of the mutations (58%), however, are clustered in exon 5. Most variants identified in patients with LCA (31/39) are missense mutations. Only six mutations result in C-terminal truncations of NMNAT1, one extends the protein, and one abolishes the start codon. The most common mutation, p.E257K, was reported in 27 cases (in one case homozygously) and proven via an NAD/ NADH assay to impede NMNAT1 activity when present in homozygous state in vivo and in a mutant construct in vitro [8] . The purpose of this study was to assess the prevalence of NMNAT1 mutations in a mixed ethnicity LCA cohort and to investigate the involvement in other progressive retinal degenerations.
METHODS

Patient cohorts:
A cohort of 693 patients with inherited retinal dystrophies participating in this study was collected over a period of 17 years. DNA was extracted from 8 ml of peripheral blood using standard salting-out procedure [18] , and the aliquots were stored at -20°C. The group consisted of 265 LCA patients (104 with and 161 without a genetic diagnosis). In addition, an extended cohort with no established causative mutation was included in the study: 271 isolated or autosomal recessive RP probands, 49 unrelated cases with autosomal dominant RP, as well as 108 persons with isolated or autosomal recessive CRD. The patients were of mixed ethnic and geographic origin (European, African, or Asian). At least 204 healthy, unrelated individuals from the Western European population were included in this study as controls. Written informed consent was obtained from all participants. The study was approved by the local Ethics Committee and adhered to the tenets of the Declaration of Helsinki. Ophthalmic examination in seven patients with NMNAT1 variants included best corrected visual acuity, ophthalmoscopy, and fundus photography, if feasible.
Nicotinamide nucleotide adenylyltransferase 1 sequence analysis: DNA samples of genetically unsolved patients with LCA were screened for mutations in all coding exons of NMNAT1. Samples underwent amplification by PCR and were analyzed with Sanger sequencing. In addition, RP and CRD samples, as well as LCA cases with previously established genetic diagnosis, were subjected to sequence analysis of exon 5 of NMNAT1. In this group, after a mutation was identified in exon 5, all exons of NMNAT1, including the noncoding exon 1, were tested with sequencing. All identified mutations were assessed for pathogenicity using the nucleotide conservation score in 44 vertebrate species (PhyloP), as well as amino acid substitution prediction programs (SIFT, PolyPhen2). To detect the p.E257K mutation in the control individuals, BspCNI restriction of amplified genomic DNA fragments was performed, followed by agarose gel electrophoresis. The other mutations were assessed in the control group using either amplification refractory mutation system (ARMS) PCR (p.H206R, p.V244A) or restriction fragment length analysis with appropriate enzymes: BsmFI (p.N18S), CviAII (p.W85R), BaeGI (p.D158H), and AseI (p.E199*). All enzymes were purchased from New England Biolabs (Hitchin, UK). All PCR reactions were performed in a volume of 20 µl containing 40 ng genomic DNA, 0.2 µM of each primer, 2 mM MgCl 2 , 1 mM dNTPs, PCR buffer provided by the manufacturer, and 0.5 U Taq polymerase (Invitrogen, Breda, The Netherlands). Primers are listed in Appendix 1. Statistical analysis was performed using IBM SPSS Statistics version 20 software (IBM, New York, NY).
Segregation analysis:
To ensure that the two compound heterozygous mutations in exon 5 were located on different alleles, and since DNA samples of the parents of the affected individuals were not available, both allelic copies of exon 5 were tested by cloning. The PCR products encompassing both mutations were cloned in the TOPO vector containing an ampicillin resistance cassette using the TOPO TA cloning kit according to the manufacturer's instructions (Invitrogen, Breda, The Netherlands). Plasmid DNA was isolated using the Roti Prep plasmid Mini kit (Carl Roth, Karlsruhe, Germany), and the vector was sequenced using the NMNAT1 exon 5 specific primer.
RESULTS
Among all patients in this study, compound heterozygous mutations were found in six families. All patients carrying NMNAT1 mutations were of European origin. Six of the identified mutations, five missense and one nonsense variant, had not been previously reported (Table 1) . Two other variants were described earlier: p.R207W and p.E257K. The pathogenicity assessment is presented in Table 2 . Single heterozygous c.769G>A (p.E257K) alleles were present in seven probands with LCA. None of the patients with RP or CRD, as well as genetically diagnosed patients with LCA, carried NMNAT1 exon 5 mutations. The control population did not show the presence of any of these alleles, with the exception of p.E257K, which was present in a heterozygous state in 1/271 persons. In all cases containing two mutations in exon 5, segregation was confirmed with allelic cloning. All sequencing results are presented in Table 1 .
All patients with compound heterozygous variants were legally blind and displayed only light or hand movements perception, depending on their age. Patient 4, the only one who did not have macular atrophy, did not retain any light perception when he was 6 years old. His fundus pictures are unavailable, since the right eye was enucleated because of corneal pain, and examination of the left eye was impossible due to corneal damage. In patient 6, macular atrophy was suspected but not possible to determine, since the degeneration was too far advanced; on funduscopy, panretinal chorioretinal atrophy was visible. In sibship 3, the boy (3.1) had distinct macular atrophy at the age of 6 months, while his sister (3.2) developed macular atrophy within the first two years of life. In all patients in whom electroretinography was performed, the signals were not detectable. Abnormal Table 3 .
DISCUSSION
Due to high energy consumption, the retina may be sensitive to deficiencies in substrates associated with cellular energy supply. NAD + , the product of a reaction catalyzed by NMNAT1, is such a substrate. NAD + is also indirectly responsible for posttranslational covalent modifications of key proteins (such as mono-and poly-ADP ribosylation) [19] . Therefore, it is not surprising that NMNAT1 mutations cause a severe form of hereditary retinal degeneration (Figure 1) . In this study, none of the patients with RP or CRD carried NMNAT1 exon 5 mutations. A separate question is the origin of the macular atrophy. Atrophic macular lesions may arise secondary to photoreceptor death, as it has been described in CRD [4] , but also in blue cone monochromacy [20] and achromatopsia [21] . In LCA, the macular lesions may evolve in time: patient 3.2 showed abnormal central pigmentations at the age of 4 months, which developed into macular atrophy at the age of 2 years. In our study, one of the seven patients (patient 4) in whom we identified NMNAT1 mutations did not exactly display this feature, but parafoveal atrophy. The genetic data gathered from our study, as well as other research, suggest that patients with LCA with NMNAT1 variants have significant residual NMNAT1 activity. Most of the variants represent combinations of nonsense mutations or missense mutations predicted by in silico prediction programs to be severe, with other alterations that are presumed to exert a milder effect on the protein. Only one patient with a homozygous null mutation (p.W169*) has been reported [9] . The lethality of Nmnat1 knockout mice suggests that human embryos with such a genotype would not be viable [16] . It is not clear how the p.W169* variant would retain any NMNAT1 activity; however, it was suggested that this phenomenon can be ascribed to NMNAT1 chaperone function, which is predicted to remain intact [9] .
The p.E257K mutation is of particular interest. Deemed to be neutral by prediction programs SIFT and PolyPhen2, this missense alteration also displays a low level of nucleotide conservation, and the physicochemical difference between these amino acids, measured with the Grantham score is only marginal. Nevertheless, a previous study showed that this mutation not only disrupts NMNAT1 activity but also has the most profound impact of all five mutations identified in that study [8] . The mechanism of this negative effect is yet unknown. Perrault and colleagues speculated that the p.E257K variant is in linkage disequilibrium with a yet undiscovered regulatory variant in the same gene, causing mRNA to be expressed at a low level. However, the experiments in question were performed by expressing recombinant NMNAT1 protein in cell lines, using constructs that did not contain regulatory parts of the gene. Another peculiar finding is the enrichment of heterozygotes for this mutation in patients with LCA compared to control groups, which was previously found to be present in 4.4% of the patient alleles versus none in 400 control alleles in one study [9] , which was a statistically significant difference. Nonetheless, the considered group consisted only of prescreened, unsolved LCA probands. In this study, we also screened our LCA cohort with patients in whom causal mutations had been previously identified. In this cohort, the p.E257K variant was present heterozygously in five LCA proband alleles (0.94%; Table  2 ) versus only one in 271 Caucasian control alleles (0.18%; Fisher's exact test, p=0.12). Moreover, when the LCA cohort was compared to European American frequency in Exome Variant Server data, a statistically significant difference was observed between the patients with LCA and the controls (0.13%, Fisher's exact test, p=0.002). It can be inferred that this variant is specific for the Western European population; however, the enrichment in patients with LCA may indicate that this variant acts as a modifier in one or several other genetic subtypes of LCA. Whole exome sequencing of these cases may further shed light on a potential modifier effect of this NMNAT1 allele on other genetic subtypes of LCA.
In addition to the p.E257K change, one other mutation, p.R207W, was detected in multiple patients. The combination of p.R207W and p.E257K variants was by far (8/311 prescreened cases from our and two other studies) the most prevalent among NMNAT1-mutated patients with LCA. Eight individuals of French origin were found to carry this combination of variants [8, 9] , which may indicate that p.R207W is a founder mutation in this population.
Two additional, potentially harmful mutations were identified only heterozygously in patients with LCA: c.12dup (p.E5Rfs*4) and a putative splice site mutation c.115+3A>G (p.?). Since they were identified in cases with LCA and RP, these mutations may be present in a compound heterozygous state with a missing "second hit" on the other allele; for example, an unidentified alteration either deep within an intron or in a regulatory sequence. The c.115+3A>G alteration, although predicted to diminish the strength of the splice site, may however be a benign alteration, since it is rather frequent in the Caucasian population ( Table 2 ). All other mutations were predicted to have a deleterious effect. Functional studies are required to evaluate the potential effect of these alterations on the protein. The indirect assessment of NMNAT1 activity by NAD measurement in patients' erythrocytes and lymphoblast cells was previously used for evaluating the pathogenicity of a given mutation. Since other tissues appear to be unaffected by NMNAT1 mutations, it cannot be certain whether the results of these measurement reflect the in vivo situation in the retina.
In conclusion, there is a strong association between NMNAT1 mutations and macular atrophy, although this feature is not always present. NMNAT1 seems to be involved in a small subset of LCA cases, since it is responsible for 2.3% of the cases in our cohort of 265 patients with LCA. Although the difference was not significant, the p.E257K mutation was enriched in a heterozygous state in individuals with LCA compared to ethnically matched controls, suggesting that this allele potentially acts as a modifier in other genetic subtypes of LCA.
APPENDIX 1. PRIMER SEQUENCES FOR THE AMPLIFICATION OF THE NMNAT1 GENE.
F: forward primer; mut: mutant-specific; R: reverse primer; wt: wild-type-specific. To access the data, click or select the words "Appendix 1."
